Describing itself as an “industrial biotechnology company,” Bota Bio has secured a total of $145 million in funding, thanks to a recent Series B funding round worth more than $100 million.
Bota Bio engineers microorganisms and biological components to make traditional manufacturing processes more sustainable. “One part of Bota Bio’s pharmaceutical business is focused on helping manufacturers of active pharmaceutical ingredients (APIs) make the transition from chemical manufacturing to biological manufacturing,” said the company’s co-founder and CEO, Cheryl Cui. Acknowledging that understand “many traditional chemistry products are very inexpensive,” Cui adds that many API manufacturers are looking to make their processes more sustainable. “Boat Bio can help with that,” she explained.
The company’s technology platform, the Bota Freeway, “takes advantage of currently available technologies and leverages a proprietary mix of digital and lab automation tools,” Cui …